TICKERNERD
Menu
TXGTXGHealthcare · Medical Devices

TXG Stock Forecast: 10X Genomics, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$68
+3.42% on the day

The 18 Wall Street analysts covering 10X Genomics, Inc. hold a median 12-month price target of $75 — +11.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 3 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$8.8B
Ticker Nerd rank
93/ 100
Median analyst target
$75
Analysts covering
18
Revenue$151.0M−12.6% y/y
Operating income−$23.0M
Net income−$17.9M
Free cash flow$15.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−19.3%
1M
−27.8%
YTD
+314.0%
1Y
+405.4%
From 52W high
−30.9%
From 52W low
+419.4%
$13
$98
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TXG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores 10X Genomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
93/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Accruals
95
Quality
94
Revisions
85
Value
74
Issuance
63
Growth
50
Volatility
35
Size
17

Momentum (96): The shares have been drifting up relative to others.

Volatility (35): The share price moves around a lot.

Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TXG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TXG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100$120Jan 26Apr 26Jul 26Oct 26TXGHigh $110Median $75Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
6 Buy12 Hold0 Sell
Low $50Median $75High $110

The green dot is the last close — the median target sits +11.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Oct 2026Morgan StanleyMaintainsEqual-Weight$40 → $70
13 Oct 2026TD CowenMaintainsHold$47 → $70
12 Oct 2026Canaccord GenuityMaintainsBuy$60 → $100
7 Oct 2026BarclaysMaintainsOverweight$52 → $110
29 Sept 2026Leerink PartnersMaintainsMarket Perform$40 → $90
29 Sept 2026Leerink PartnersMaintainsMarket Perform—
28 Sept 2026Argus ResearchInitiatesBuy$110
28 Sept 2026Argus ResearchInitiatesBuy—
28 Sept 2026Piper SandlerMaintainsNeutral—
28 Sept 2026Piper SandlerMaintainsNeutral$47 → $80
9 Sept 2026UBSMaintainsNeutral$20 → $68
9 Sept 2026UBSMaintainsNeutral—
1 Sept 2026RBC CapitalInitiatesSector Perform—
1 Sept 2026RBC CapitalInitiatesSector Perform$70
12 Aug 2026Stephens & Co.MaintainsOverweight$50 → $65
12 Aug 2026Stephens & Co.MaintainsOverweight—
10 Aug 2026Canaccord GenuityMaintainsBuy—
10 Aug 2026Canaccord GenuityMaintainsBuy$50 → $60
10 Aug 2026Piper SandlerMaintainsNeutral—
10 Aug 2026Piper SandlerMaintainsNeutral$42 → $47

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

TXG appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TXG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, 10X Genomics, Inc. returned +405.4% against +12.9% for the S&P 500, dividends included.

TXG vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500600700Jan 26Apr 26Jul 26Oct 26TXGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TXG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

10X Genomics, Inc. (TXG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−192.9×

Cheaper than 99% of US stocks

Price / sales
14.3×

Cheaper than 11% of US stocks

Price / book
10.7×

Cheaper than 9% of US stocks

EV / EBITDA
−195.0×

Cheaper than 98% of US stocks

Growth & margins
Revenue growth (YoY)
−12.7%

Higher than 14% of US stocks

Earnings growth (YoY)
−12.6%

Higher than 25% of US stocks

Gross margin
74.5%

Higher than 87% of US stocks

Operating margin
−15.2%

Higher than 23% of US stocks

Net margin
−12.2%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−9.4%

Higher than 36% of US stocks

Return on assets
−5.0%

Higher than 32% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

10X Genomics, Inc. (TXG) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • 10X Genomics, Inc. has a market value of $8.8B and an enterprise value of $8.0B.

  • Revenue in the twelve months to 30 June 2026: $616.9M. The latest quarter shrank 12.7% year on year.

  • Net income over the same four quarters: −$75.1M, a −12.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.59.

  • Free cash flow in the twelve months to 30 June 2026: $121.4M.

  • Shares outstanding: 130.3M.

  • Trailing P/E: −192.9×; forward P/E: 880.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • 10X Genomics, Inc. employs 1,178 people — $524K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

TXG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
TXG10X Genomics, Inc.$8.8B93
BRKRBruker Corp.$8.6B90
BIOBio-Rad Laboratories, Inc.$10.0B92
GMEDGlobus Medical, Inc.$10.7B97
PODDInsulet Corp.$10.7B91
PENPenumbra, Inc.$12.6B76
HAEHaemonetics Corp.$5.5B99

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own 10X Genomics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TXG news & analysis

10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis

PRNewsWire · 2 Nov 2026positive

10x Genomics announced the commercial launch of Sentira Single Cell, a cloud-based agentic analysis application for Chromium data. Powered by Anthropic’s Claude, it lets researchers analyze data using natural language.

Why it matters — TXG watchers may note the launch as a new software offering intended to help researchers move from scientific questions to experimental conclusions.

3 Promising Genomics Stocks to Add to Your Portfolio Now

Zacks Investment Research · 30 Oct 2026positive

Zacks Investment Research highlighted ILMN, QURE and TXG among genomics stocks, citing the expansion of precision medicine and gene editing.

Why it matters — TXG is included in the article’s list of genomics stocks as the markets expand.

10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference

PRNewsWire · 27 Oct 2026neutral

10x Genomics announced that members of its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in London on November 17 at 4:30 p.m.

Why it matters — TXG watchers may note the scheduled opportunity for company management to speak at the healthcare conference.

10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research

Zacks Investment Research · 8 Oct 2026positive

10x Genomics is partnering with Fred Hutchinson Cancer Center on cancer biomarker research, using single-cell and spatial technologies to advance precision oncology in two cancer types.

Why it matters — The collaboration highlights TXG’s single-cell and spatial technologies in cancer research with a major cancer center.

FAQ

Frequently asked questions about TXG stock

What is the TXG stock price forecast for 2026-2027?

The 18 Wall Street analysts covering 10X Genomics, Inc. have a median 12-month price target of $75, with estimates ranging from $50 to $110. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TXG stock a buy right now?

Of the 18 analysts covering 10X Genomics, Inc., 6 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 10X Genomics, Inc. 93 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TXG?

As at 3 Nov 2026, 10X Genomics, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will TXG stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +11.1% from the last close, and Ticker Nerd's factor model ranks 10X Genomics, Inc. 93 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TXG stock forecast for 2030?

No analyst covering 10X Genomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TXG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $110 over the next 12 months.

How has TXG stock performed over the past year?

10X Genomics, Inc. returned +405.4% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does 10X Genomics, Inc. do?

10x Genomics Inc. Class A Common Stock represents ownership in 10x Genomics, a life science technology company focused on products that help researchers study biology at high resolution.

What is the latest news on TXG?

The most recent item we track (PRNewsWire, 2 Nov 2026): "10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis". 10x Genomics announced the commercial launch of Sentira Single Cell, a cloud-based agentic analysis application for Chromium data. Powered by Anthropic’s Claude, it lets researchers analyze data using natural language.

Company

About 10X Genomics, Inc.

10x Genomics Inc. Class A Common Stock represents ownership in 10x Genomics, a life science technology company focused on products that help researchers study biology at high resolution. The company develops integrated instruments, consumables, and software used for single-cell and spatial biology workflows, supporting applications such as gene expression analysis, immune profiling, chromatin accessibility, spatial transcriptomics, and in situ exploration of tissue biology. Its main product families include the Chromium platform, the Chromium X series, Visium, and Xenium, which are used by academic researchers, pharmaceutical companies, biotechnology firms, and other scientific organizations. 10x Genomics serves global markets across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. The stock is commonly associated with the broader life sciences tools and services sector, where the company plays a specialized role in enabling advanced biological research and data generation.

CEO Dr. Serge Saxonov Ph.D. · 1,178 employees · United States · https://www.10xgenomics.com